|
|
|
|
Vol. 57, Issue 5, 857-864, May 2000
2-Adrenoceptor
Activation
Department of Thoracic Medicine (J.C.W.M., T.K., P.J.B.), Imperial College School of Medicine, National Heart and Lung Institute, London, UK; and Department of Molecular Pharmacology (A.F.R., C.R.S.E., J.Z.), University of Groningen, AV Groningen, The Netherlands
| |
Abstract |
|---|
|
|
|---|
Histamine, released from activated mast cells, causes
bronchoconstriction mediated by H1 receptors, whereas
2-agonists are widely used for the relief of
bronchoconstriction. In this study, we examined the effects of the
2-adrenoceptor agonist, fenoterol, on the expression of
H1 receptors at the mRNA and protein levels, and functional
responses. Incubation of bovine tracheal smooth muscle with fenoterol
(10
7 M) for 2 h increased H1 receptor
mRNA (maximum ~190%). The number of H1 receptors was
increased after 12 and 18 h without any change in binding
affinity. In the contraction experiments, the concentration-response curves for histamine-induced contraction were shifted significantly to
the left after 18-h exposure to fenoterol, consistent with the increase
in receptor number. The fenoterol-induced increase in H1
receptor mRNA was concentration-dependent and was abolished by
propranolol and ICI 118551, but not by CGP 20712A, indicating that
fenoterol acts via
2-adrenoceptors. These effects were
mimicked by other cAMP-elevating agents forskolin and prostaglandin
E2, and by the stable cAMP analog 8-bromo-cAMP.
Cycloheximide alone produced superinduction of H1 receptor
mRNA and augmented the fenoterol-induced increase in H1
receptor mRNA. Fenoterol increased both the stability and the
transcription rate of H1 receptor mRNA. Pretreatment with
dexamethasone did not prevent fenoterol-induced up-regulation of
H1 receptor mRNA. Thus, fenoterol increases the expression
of airway smooth muscle H1 receptors via activation of the
cAMP system through increased gene transcription and mRNA stability.
This mechanism may be involved in the adverse responses encountered
with the clinical use of short-acting
2-agonists.
| |
Introduction |
|---|
|
|
|---|
Histamine
is an important mediator of airway smooth muscle contraction, which is
mediated via H1 receptors (Chand and Sofia, 1995
). H1 receptors have now been cloned from
several species (Yamashita et al., 1991
; Fujimoto et al., 1993
; Horio
et al., 1993
; Fukui et al., 1994
; Inoue et al., 1996
). Activation of
histamine H1 receptors leads to the formation
of inositol 1,4,5-trisphosphate [Ins(1,4,5)P3] and diacylglycerol from
phosphatidylinositol 4,5-bisphosphate hydrolysis (Leurs et al.,
1995
). Ins(1,4,5)P3 binds to a specific receptor
on endoplasmic/sarcoplasmic reticulum, which leads to the release of
Ca2+ from intracellular stores, resulting in an
initial transient contractile response, whereas diacylglycerol
activates protein kinase C (PKC), which is believed to be responsible
for the sustained phase of the smooth muscle contraction (Rasmussen et
al., 1987
). H1 receptors are expressed in airway
smooth muscle and may be regulated at the transcriptional level. PKC
phosphorylation sites have recently been identified in the third
intracellular loop of the histamine H1 receptors.
We have shown that phorbol esters, which activate PKC, result in a
marked down-regulation of H1 receptors due to
uncoupling of the receptor and a reduction in transcription (Pype et
al., 1998
).
2-Adrenoceptor agonists have been widely used
as bronchodilators for the relief of the symptoms of asthma, because
they act as functional antagonists that counteract multiple
bronchoconstrictors.
2-Adrenoceptors are
localized to airway smooth muscle of all airways from trachea to
terminal bronchioles (Barnes, 1995
). However, the use of high doses of
2-agonists has been linked to the development of bronchial hyper-responsiveness (Taylor et al., 1993
; Wahedna et al.,
1993
) and an increase in asthma exacerbations and mortality (Suissa et
al., 1994
; Barrett and Strom, 1995
). Sustained use of
2-adrenoceptor agonists is associated with
loss of protection to bronchoconstrictors, such as adenosine, allergen,
methacholine, and histamine (O'Connor et al., 1992
; Cockcroft
and Swystun, 1996
).
2-Adrenoceptors are
coupled via Gs protein to the
membrane-bound enzyme adenylyl cyclase to increase production of cAMP.
The formation of cAMP leads to the characteristic cellular response via
the activation of a specific protein kinase, protein kinase A (PKA), by
dissociating a regulatory (inhibitory) subunit. PKA then phosphorylates serine and threonine residues on specific proteins, such as regulatory proteins within the cell, which results in relaxation of airway smooth muscle. Evidence has emerged to support the concept of regulatory "cross talk" between the
2-adrenoceptor/cAMP signaling pathway and the phospholipase
C-coupled/Ins(1,4,5)P3 transmembrane signaling mechanism (Madison and Brown, 1988
; Schramm et al.
1995
; Zaagsma et al., 1997
).
This study was thus undertaken to investigate the effects of the
2-adrenoceptor agonist fenoterol on the
expression of the histamine H1 receptor gene and
functional receptors in bovine tracheal smooth muscle. We have
previously shown that this tissue expresses H1
receptors with no detection of H2 receptors (Pype et al., 1998
). Because glucocorticoids counteract the effect of
2-adrenoceptor agonists, the effects of
steroid in the presence of fenoterol on the expression of the histamine
H1 receptor gene were also investigated.
| |
Experimental Procedures |
|---|
|
|
|---|
Materials.
[
-32P]dCTP (3000 Ci/mmol) was purchased from Amersham International (Amersham, UK).
[32P]UTP (800 Ci/mmol) and
[pyridimyl-5-3H]mepyramine (pyrilamine; 20 Ci/mmol) were from DuPont/NEN (Boston, MA). Fenoterol hydrobromide,
(
)-isoproterenol hydrochloride, histamine dihydrochloride, and
triprolidine were from Sigma. Methacholine chloride and HEPES-buffered
Dulbecco's modified Eagle's medium (DMEM) were either from Sigma or
ICN Biomedicals (Costa Mesa, CA). Scintillant Filtron-X was from
National Diagnostics (Hull, UK). Tissue culture supplies were from Life
Technologies (Paisley, UK). All other chemicals were of reagent grade
and from standard sources.
Tissue Preparation and Incubation.
Fresh bovine tracheae
were obtained from the abattoir and placed in oxygenated
Krebs-Henseleit solution [(in millimolar): NaCl 118, KCl 5.9, MgSO4 1.2, CaCl2 2.5, NaH2PO4 1.2, NaHCO3 25.5, and glucose 5.6] at room
temperature. The tracheal smooth muscle layer was dissected after
stripping off epithelium; mucosa and connective tissue and smooth
muscle pieces were prepared in Krebs-Henseleit solution at room
temperature. After washing, incubation was performed in HEPES-buffered
DMEM supplemented with 10% fetal calf serum, 2 mM
L-glutamate, 100 I.U./ml penicillin, 100 µg/ml
streptomycin, and 0.25 µg/ml amphotericin B at 37°C in a shaker
incubator. For molecular and binding studies, pieces of bovine tracheal
smooth muscle were placed in T-75 flasks and incubated in the absence or presence of 10
9 to
10
5 M fenoterol for the indicated periods of
time. The tissues were then frozen and kept at
70°C for RNA
extraction and membrane preparation. To examine whether the effects of
fenoterol were mediated via specific receptor subtypes, propranolol
(nonselective
-adrenoceptor antagonist; 10
7
M), ICI 118551 (selective
2-adrenoceptor
antagonist; 10
7 M), or CGP 20712A (selective
1-adrenoceptor antagonist;
10
7 M) were added for 1 h before
10
7 M fenoterol for a further 2 h.
Preincubation of bovine tracheal smooth muscle with the protein
synthesis inhibitor cycloheximide (10 µg/ml) for 1 h before
addition of 10
7 M fenoterol for a further
2 h was carried out to assess whether new synthesis of protein(s)
was required. Incubation of bovine tracheal smooth muscle with a direct
adenylyl cyclase activator, forskolin (10
5 M),
a nonhydrolyzable analog of cAMP, 8-bromo-cAMP
(10
3 M), or other cAMP-elevating agents such as
prostaglandin E2 (PGE2; 10
6 M) for 2 h was carried out to see
whether the effect of fenoterol is mediated by the elevation of cAMP.
The half-life of the H1 receptor mRNA in control
and fenoterol-treated tissues was measured by incubation in the absence
and presence of 10
7 M fenoterol for 2 h
before the addition of 5 µg/ml actinomycin D for various times
(Rodgers et al., 1985
). In some experiments, incubation of bovine
tracheal smooth muscle with 10
7 M fenoterol for
2 h was carried out in the presence of various concentrations of
dexamethasone (10
9 to
10
6 M).
7 M or 10
5 M
fenoterol, to 10
6 M dexamethasone alone or in
combination with 10
7 M fenoterol, or to vehicle
(three to four smooth muscle strips in 10 ml of the same medium used
for the incubation of muscle pieces in a 25-cm2
cell culture flask) at 37°C in a shaking incubator.
Radioligand Receptor Binding Assay.
Bovine trachealis
(control and fenoterol-treated, 10
7 M for
various times) was homogenized using a Polytron in ice-cold 50 mM
Tris-HCl buffer, pH 7.5, containing 0.32 M sucrose, then centrifuged at
1000g for 10 min to remove unhomogenized debris; the
supernatant was centrifuged at 40,000g for 20 min and the
resulting pellet was washed and centrifuged again. The final pellet was
resuspended in incubation buffer (50 mM Tris-HCl, pH 7.5, at 30°C) to
give a final protein concentration of 3 to 5 mg/ml and was stored at
70°C until required for use. Protein was determined by the method of Lowry et al. (1951)
with bovine serum albumin used as a standard.
Contraction Measurements.
After 18-h exposure to drugs or
vehicle, smooth muscle strips were washed twice and then mounted in
20-ml organ baths for isotonic recording under a 0.5-g preload in
gassed Krebs-Henseleit buffer at 37°C. After two 30-min equilibration
periods with a change of buffer in between, the strips were
precontracted twice by cumulative administration of methacholine
(10
7 to 10
5 M and
10
7 to 10
4 M,
respectively), followed by washing periods of 60 min; in between, maximal relaxation was established with 10
7 M
(
)-isoproterenol immediately followed by a 15-min washing period.
Subsequently, cumulative concentration-response curves to histamine
were constructed in the presence of 10
6 M
timolol, to ensure elimination of
-adrenoceptor activation; experiments were performed in duplicate on five independent occasions, except for dexamethasone plus fenoterol (n = 4).
Histamine-induced contractile responses were expressed as a percentage
of the response to 10
4 M methacholine
as assessed in the second precontraction curve in each individual
smooth muscle strip.
Northern Blot Analysis.
Total RNA was isolated by
phenol/chloroform extraction and isopropanol precipitation (Chomczynski
and Sacchi, 1987
). An mRNA isolation kit system (PolyATtract IV;
Promega, Southampton, UK) was used to prepare
poly(A)+ RNA according to the manufacturer's
instructions. Samples of poly(A)+ RNA were
size-fractionated on a 1% agarose/formaldehyde gel and blotted onto
nylon membrane (Magna, MA) by capillary action.
-32P]dCTP. The blot was prehybridized for 4 to 5 h in 50% formamide, 5 × standard sodium citrate (SSC),
5 × Denhardt's solution, 0.1% SDS, 10 mM
NaH2PO4, and 100 mg/ml
sonicated denatured salmon sperm DNA, and then hybridized with
32P-labeled cDNA probes for 12 to 16 h at
42°C. After hybridization, the blot was washed at high stringency in
0.1 × SSC/0.1% SDS at 55°C for 30 min. The blot was exposed to
Kodak OMAT XS film at
70°C with an intensifying screen for 1 to 3 days. The blot was hybridized first to a
32P-labeled histamine H1
receptor cDNA probe and subsequently to a GAPDH cDNA probe after
stripping. The autoradiograms were scanned with a laser densitometer
(Gel Documentation and Analysis System GDS8000; UVP, Cambridge, UK).
The amount of histamine H1 receptor mRNA was
quantified relative to the amount of GAPDH mRNA on the same filter.
Nuclear Run-On Transcription Assay.
Nuclear run-on
transcription assays were performed to determine whether fenoterol
changed the transcription rate of histamine H1
receptor gene. Nuclei were isolated from frozen bovine tracheal smooth
muscle after incubating with or without fenoterol
(10
7 M) for 2 h and stored at
70°C in
Keller storage buffer [10 mM Tris-HCl, pH 7.5, 5 mM
MgCl2, 0.5 M Sorbitol, 2.5% Ficoll (400,000 mol.
wt.), 0.008% spermidine, 1 mM dithiothreitol, and 50%
glycerol] at 5 × 107 nuclei/100 µl. Each
reaction (final volume, 0.4 ml) was carried out in the presence of
5 × 107 isolated nuclei, 40 mM Tris-HCl (pH
8.3), 150 mM NH4Cl, 7.5 mM MgCl2, 0.625 mM ATP, 0.313 mM GTP, 0.313 mM CTP
(Promega), 0.5 mCi of [32P]UTP, and 120 units/ml recombinant ribonuclease (RNase) inhibitor. Transcription
reactions were allowed to proceed for 30 min at 27°C before
termination by the addition of 40 units of recombinant RNase inhibitor
and 75 units of RQ-1 DNase. After DNase and proteinase K treatments,
the radiolabeled RNA formed was purified by phenol-chloroform extraction and precipitated with ethanol three times in the presence of
1.33 M ammonium acetate. An equal number of counts from each sample was
added to slot blots, three slots on the same blot on which 10 µg of
either pGEM-3Z plasmid (as control) or plasmid containing inserts of
bovine histamine H1 receptor cDNA or rat GAPDH
cDNA have been immobilized to a nylon membrane. After hybridization for
72 h at 42°C, the blots were washed at a final stringency of
0.1 × SSC and 0.1% SDS at 55°C, including a 30-min digestion with 1 mg/ml RNase A and 20 units/ml RNase T1 at 37°C to digest any
single-stranded RNA not hybridized to DNA. After autoradiography, the
film was scanned by laser densitometry and quantified by calculating the ratio of histamine H1 receptor cDNA signal to
GAPDH cDNA signal.
Statistical Analysis. Data were presented as means ± S.E. For multiple comparison of different groups, analysis of variance was used. Data that appeared statistically significant were compared by paired or unpaired Student's t test, with Bonferroni correction. A value of P < .05 was considered to be significant.
| |
Results |
|---|
|
|
|---|
Radioligand Binding Studies.
Saturation studies performed with
the selective histamine H1 receptor antagonist
[3H]pyrilamine revealed a single class of
high-affinity binding sites in airway smooth muscle. Treatment of
airway smooth muscle with fenoterol causes a time-dependent increase in
the number (Bmax) of histamine
H1 receptors (Fig.
1), without any change in binding
affinity (Kd; 1.5 ± 0.2 versus
1.7 ± 0.1 nM, 1.7 ± 0.2 versus 1.6 ± 0.1 nM, 1.7 ± 0.2 versus 1.7 ± 0.2 nM, and 1.6 ± 0.1 versus 1.7 ± 0.1 nM for 2, 6, 12, and 18 h, respectively).
|
Contraction Studies.
Histamine produced
concentration-dependent contractions in control bovine tracheal smooth
muscle strips, with pD2 (
log
EC50) values of 5.95 ± 0.10 (n = 5). Concentration-response curves after 18-h
exposure to fenoterol were shifted significantly, albeit only
moderately, to the left by 0.19 ± 0.06 (10
7 M fenoterol) and 0.24 ± 0.08 (10
5 M fenoterol) log units,
reaching pD2 values of 6.14 ± 0.12 and 6.19 ± 0.14 (both P < .05 compared with
control); there were no significant changes in maximum contraction
levels as compared with control. Histamine-induced contractions were
shifted to the right, albeit not as significantly, by 0.18 ± 0.08 log units after 18-h exposure to dexamethasone
(10
6 M), reaching
pD2 values of 5.77 ± 0.09. Dexamethasone
prevented the increase in contractile potency induced by
10
7 M fenoterol, resulting in
pD2 values of 5.84 ± 0.11 (not
significantly different from control; P < .05 compared
with fenoterol alone) (Fig. 2).
|
Histamine H1 Receptor Gene Expression.
Northern
blot analyses of airway smooth muscle revealed the presence of a 3.0-kb
transcript corresponding to the histamine H1
receptor mRNA. Short incubations (up to 2 h) of airway smooth muscle with fenoterol resulted in a maximal (92%) increase in the
steady-state levels of histamine H1 receptor
mRNA, which returned to baseline with longer incubation periods (up to
18 h; Fig. 3). A fenoterol-induced
increase in histamine H1 receptor mRNA after 2 h was not detected until concentration reached
10
7 M (Fig. 4).
Preincubation with the nonselective
-adrenoceptor antagonist,
propranolol, and the selective
2-adrenoceptor
antagonist, ICI 118551, completely inhibited the fenoterol-induced
increase in steady-state mRNA at 2 h, whereas the selective
1-adrenoceptor antagonist, CGP 20712A, had no
effect (Fig. 5). This indicated that the
effect of fenoterol on histamine H1 receptor mRNA
was mediated entirely by
2-adrenoceptors.
|
|
|
|
|
|
|
6 M.
|
| |
Discussion |
|---|
|
|
|---|
These studies demonstrate transregulation of histamine
H1 receptors by
2-adrenoceptor activation in airway smooth
muscle and implicate a cAMP-dependent process in the up-regulation of histamine H1 receptors.
Specific [3H]pyrilamine binding to histamine
H1 receptors in airway smooth muscle membranes
was saturable and best described by interaction of the radioligand with
a single class of high affinity binding sites. Stimulation of
2-adrenoceptors resulted in a time-dependent
increase in histamine H1 receptor density after
12 and 18 h of incubation. However, treatment with fenoterol led
to a rapid increase in histamine H1 receptor
mRNA, reaching a maximum at 2 h and returning to control level by
12 h of incubation. The increase in histamine
H1 receptor mRNA occurred well before the
increase in histamine H1 receptor number. Hence,
the increased receptor density is likely a result of increased mRNA
level, leading to increased receptor translation and expression at the
cell surface. This fenoterol-induced increase in the histamine
H1 receptor mRNA level was antagonized by
coincubation with the nonselective
-adrenoceptor antagonist
propranolol and the selective
2-adrenoceptor
antagonist ICI 118551 but not the selective
1-adrenoceptor antagonist CGP 20712A,
confirming a
2-adrenoceptor-mediated effect.
To gain insight into the mechanism whereby fenoterol induced histamine
H1 receptor mRNA up-regulation, we investigated
the effect of the protein synthesis inhibitor, cycloheximide. Following cycloheximide treatment alone, there was a marked accumulation of the
histamine H1 receptor mRNA, to a similar extent
as with fenoterol. This superinduction is thought to result from the
loss of labile transcriptional repressors and mRNA-degrading enzymes and is usually regarded as a direct consequence of the inhibition of
protein synthesis (Mahadevan and Edwards, 1991
). However, in this
study, we did not investigate the exact mechanism by which cycloheximide causes superinduction of histamine
H1 receptor gene. Nevertheless, in the presence
of cycloheximide, fenoterol caused an additional increase in histamine
H1 receptor mRNA, an additive effect that
providing evidence that, subsequent to
2-adrenoceptor stimulation, de novo protein
synthesis was not required for the fenoterol-enhanced expression of
histamine H1 receptor mRNA.
The increase in the steady-state level of histamine
H1 receptor mRNA after
2-adrenoceptor activation was mimicked by
forskolin (an agent that directly stimulates adenylyl cyclase),
8-bromo-cAMP (a nonhydrolyzable analog of cAMP), and
PGE2 (another agent-elevating intracellular cAMP
level via receptor activation). These data strongly indicate a
cAMP-dependent process in the up-regulation of histamine
H1 receptor mRNA. The presence of a putative
cAMP-response element in the 5'-flanking region of the bovine histamine
H1 receptor gene would be expected, given the
regulation of histamine H1 receptor mRNA by cAMP
in this study. However, no sequence data are available for the bovine
histamine H1 receptor gene promoter except from human studies (De Backer et al., 1998
).
Experiments were also performed to determine whether the
fenoterol-induced up-regulation of histamine H1
receptor mRNA level was a consequence of alteration in mRNA stability
or changes in the rate of gene transcription. Following fenoterol
treatment, we found an increase in the histamine
H1 receptor mRNA half-life that may partially
explain the up-regulation.
-Adrenoceptor agonists have previously
been shown to affect mRNA stability, such as m2 muscarinic
acetylcholine receptor mRNA levels in chicken heart cells (Jackson and
Nathanson, 1995
) and tachykinin NK2 receptor mRNA
in bovine tracheal smooth muscle (Katsunuma et al., 1999
). The rate of
transcription of newly synthesized histamine H1
receptor mRNA measured by a nuclear run-on assay was also increased by approximately 60% after fenoterol treatment for 2 h, compared with control, suggesting that both an increase of histamine
H1 receptor mRNA stability and an increased rate
of transcription of histamine H1 receptor gene
are likely to contribute to the transcriptional and
post-transcriptional up-regulation of histamine H1 receptors.
The contraction experiments suggest that
2-adrenoceptor-mediated up-regulation of
histamine H1 receptor number may have functional implications. Thus, although the concentration-response curves for
histamine-induced contraction were shifted to the left to only a
limited extent after prolonged exposure to fenoterol (1.5-fold after
10
7 M, 1.7-fold after
10
5 M), this increase in contractile potency
agrees extremely well with the actual level to which receptor number
was increased (i.e., 1.7-fold after 18-h fenoterol
10
7 M). Furthermore, the decrease in histamine
contractile potency after 18-h pre-exposure to dexamethasone was also
relatively small in terms of shift of the concentration-response curve
(1.5-fold), but, similar to the effect observed after fenoterol, this
might have functional implications in that the actual contraction
levels at low concentrations of the spasmogen were clearly decreased (e.g., from 21 to 14% at 3 × 10
7 M
histamine). This regulatory mechanism may well contribute to the
improvement of bronchial hyper-responsiveness to histamine in patients
suffering from asthma and taking corticosteroids as observed in
numerous studies, in addition to the well known anti-inflammatory properties (Barnes et al., 1998
). The mechanism by which dexamethasone decreased histamine contractile potency does not appear to reside in
direct control of mRNA expression. It has been shown, however, that the
exposure of cultured human airway smooth muscle cells to dexamethasone
for 22 h resulted in an inhibition of histamine-induced inositol
phosphates accumulation as well as calcium mobilization (Hardy
et al., 1996
). This mechanism might explain the effect observed in this
study. It remains to be established whether reductions in histamine
H1 receptor number and/or alterations in the
receptor-G-protein interaction play a role in this functional desensitization.
Similar to our findings on NK2 receptor
expression, dexamethasone completely prevented the increase in
histamine contractile potency as induced by prolonged exposure to
fenoterol. This protection may be explained by the 37% reduction of
fenoterol-induced up-regulation of histamine H1
receptor mRNA in the presence of the highest dose of
glucocorticosteroid, in addition to the putative inhibition of
histamine-induced intracellular signaling, which are in contrast to complete protection against fenoterol-induced up-regulation of
tachykinin NK2 receptor mRNA in the same tissue
(Katsunuma et al., 1999
). Recent observations have shown that
salbutamol and salmeterol (partial
2-agonists)
caused direct activation of the glucocorticoid receptors in human lung
fibroblasts and vascular smooth muscle cells (Eickelberg et al., 1999
).
Thus, if this effect on glucocorticoid receptors would also occur with fenoterol in bovine trachealis, this would suggest that the effect of
2-agonist alone is the result of
fenoterol-induced up-regulation plus possibly glucocorticoid
receptor-mediated down-regulation of histamine H1
receptor mRNA. However, we have previously found that
dexamethasone alone had no effect on the steady-state level of
histamine H1 receptor mRNA (J. L. Pype,
unpublished observation), in contrast to the fact that dexamethasone
indeed regulates histamine H1 receptor coupling
in human cultured airway smooth muscle (Hardy et al., 1996
). The
observed differences may be due to different mechanisms. From the
structure of human histamine H1 receptor gene (De
Backer et al., 1998
), no glucocorticoid response element is present in
its promoter, but multiple potential AP-1 binding sites are present in
the region. The mechanism by which fenoterol increases the expression
of histamine H1 receptor mRNA appears to be
independent of new protein synthesis, in contrast to the requirement
for de novo protein synthesis for fenoterol-induced up-regulation of
tachykinin NK2 receptor mRNA, suggesting that dexamethasone inhibits new protein synthesis.
2-Adrenoceptor agonists are the most effective
bronchodilators currently available for the treatment of asthma.
However, there are still some concerns that excessive use of
2-adrenoceptor agonists in some patients may
contribute to asthma morbidity or mortality (Chung, 1993
). The regular
use of inhaled
2-adrenoceptor agonists such as
fenoterol has been associated with an increased risk of death or near
death from asthma (Spitzer et al., 1992
). Thus, if the increase in
histamine H1 receptor expression as observed here
would also occur in human airway smooth muscle in vivo, this might
contribute to the adverse effects with the regular or sustained use of
2-adrenoceptor agonists. Consistent
with the contraction experiments, contraction levels were increased
markedly especially at low concentrations of the spasmogen (e.g., from
21% to approximately 35% of methacholine maximum at 3 × 10
7 M histamine). Such increased contraction,
and thus shortening of the muscle, would result in quite important
reductions in airflow, given that this is dependent on airway radius.
In summary, the molecular transregulation of histamine
H1 receptors by
2-adrenoceptor activation, which results in
up-regulation of the functional histamine H1
receptors, is preceded by an increase in steady-state levels of mRNA
and is controlled at the gene level through a dual mechanism involving
transcriptional and post-transcriptional mechanisms. The
up-regulation of histamine H1 receptor mRNA could also be mimicked by other agents that elevate cAMP levels, suggesting that cAMP has a role in this process.
| |
Footnotes |
|---|
Received November 23, 1999; Accepted February 2, 2000
1 Present address: Department of Allergy, National Children's Research Center 3-35-31, Taishido, Setagaya-ku, Tokyo, 154-8509, Japan.
This work was funded by a GlaxoWellcome research grant, an Imperial College Initiative Award, UK, and the Netherlands Asthma Foundation.
Send reprint requests to: Dr. Judith C. W. Mak, Department of Thoracic Medicine, Imperial College, National Heart & Lung Institute, Dovehouse St., London SW3 6LY, United Kingdom. E-mail: j.mak{at}ic.ac.uk
| |
Abbreviations |
|---|
Ins(1,4,5)P3, inositol 1,4,5-trisphosphate; PKA, protein kinase A; PKC, protein kinase C; PGE2, prostaglandin E2; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; DMEM, Dulbecco's modified Eagle's medium; SSC, standard sodium citrate.
| |
References |
|---|
|
|
|---|
-agonists in asthma: A review.
J R Soc Med
86:
96-100[Medline].
2-agonists.
Thorax
51:
1051-1056
2-adrenergic receptor agonists in primary human lung fibroblasts and vascular smooth muscle cells.
J Biol Chem
274:
1005-1010
2-Adrenoceptor agonist-induced upregulation of tachykinin NK2 receptor expression and function in airway smooth muscle.
Am J Respir Cell Mol Biol
21:
409-417
2-agonists.
N Engl J Med
327:
1204-1208[Abstract].
-agonists and the risk of death and near death from asthma.
N Engl J Med
326:
501-506[Abstract].
-agonists.
Am J Respir Crit Care Med
149:
604-610[Abstract].
-agonist in asthma: Effects on exacerbations and lung function.
Thorax
48:
134-138This article has been cited by other articles:
![]() |
N. J. Fairbank, S. C. Connolly, J. D. MacKinnon, K. Wehry, L. Deng, and G. N. Maksym Airway smooth muscle cell tone amplifies contractile function in the presence of chronic cyclic strain Am J Physiol Lung Cell Mol Physiol, September 1, 2008; 295(3): L479 - L488. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Swan, S. A. Richards, N. P. Duroudier, I. Sayers, and I. P. Hall Alternative Promoter Use and Splice Variation in the Human Histamine H1 Receptor Gene Am. J. Respir. Cell Mol. Biol., July 1, 2006; 35(1): 118 - 126. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Giembycz and R. Newton Beyond the dogma: novel {beta}2-adrenoceptor signalling in the airways. Eur. Respir. J., June 1, 2006; 27(6): 1286 - 1306. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. B. Whitaker, B. J. Limberg, and J. S. Rosenbaum Vascular Endothelial Growth Factor Receptor-2 and Neuropilin-1 Form a Receptor Complex That Is Responsible for the Differential Signaling Potency of VEGF165 and VEGF121 J. Biol. Chem., June 29, 2001; 276(27): 25520 - 25531. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||